

HUMANOVA PHARMACOVIGILANCE, TECHNOVIGILANCE, AND COSMETOVIGILANCE POLICY

Our policy outlines the guidelines for managing the safety information resulting from the use of or exposure to our products (medicines, medical devices, and cosmetics) by patients, users, healthcare professionals, among others, in order to identify, collect, evaluate, and prevent adverse events or any other issue related to their safety, ensuring confidentiality in the handling of information gathered by our Pharmacovigilance, Technovigilance, and Cosmetovigilance team.

This policy is crucial for monitoring the safety and efficacy of our products, helping to detect and manage associated risks, and ensuring that the benefits outweigh the risks.

If you become aware of an adverse event associated with the use of a HUMANOVA product, please report it as soon as possible to our Pharmacovigilance, Technovigilance, and Cosmetovigilance team through our web form: <https://humanovalab.com/es/notificacion-de-eventos-adversos/> or through the official notification channels of each subsidiary:

Humanova Brazil:	E-mail Address: farmacovigilancia@farmarin.com.br Phone Number: +55 11 24028800 (ext. 297)
Humanova Chile:	E-mail Address: farmacovigilancialsa@humanovalab.com Phone Number: +569 85273520
Humanova Colombia:	E-mail Address: farmacoytecnovigilanciacol@humanovalab.com Phone Number: + 57 604 2044590
Humanova Ecuador:	E-mail Address: farmacovigilancia@medifarma.ec Phone Number: +593 964110578
Humanova Paraguay:	E-mail Address: sidb@humanovalab.com Phone Number: +59 521 683883
Humanova Peru:	E-mail Address: farmacovigilancia@humanovalab.com / tecnovigilancia@humanovalab.com / cosmetovigilancia@humanovalab.com Phone Number: +51 1 332 6200 (ext. 5211/5230)
Humanova Portugal:	E-mail Address: farmacovigilancia@atral.pt Phone Number: +351 214278610
Humanova Uruguay:	E-mail Address: farmacovigilancia-uruguay@humanovalab.com Phone Number: +598 2215 2302 (ext. 6)

All collected information will remain confidential, securely protected, and disclosed only with the reporter's consent.